News articles about Compugen (NASDAQ:CGEN) have been trending somewhat negative this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Compugen earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.5775573789223 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Compugen (NASDAQ:CGEN) opened at $2.80 on Tuesday. The company has a market capitalization of $143.17, a P/E ratio of -3.94 and a beta of 0.58. Compugen has a 12-month low of $2.25 and a 12-month high of $5.40.
Compugen (NASDAQ:CGEN) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). research analysts predict that Compugen will post -0.73 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Somewhat Negative News Coverage Somewhat Unlikely to Impact Compugen (NASDAQ:CGEN) Share Price” was originally published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/compugen-cgen-receives-news-impact-score-of-0-02/1819993.html.
Compugen Company Profile
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.